Biofi manufactures diabetes management devices that utilize continuous glucose monitoring technology to provide real-time blood sugar data. This enables users to make informed decisions about their insulin administration and dietary choices, improving overall diabetes control and reducing the risk of complications.
Funding
Funding not disclosed
Founders
Product
Problem
Managing diabetes effectively requires frequent blood glucose monitoring, which can be inconvenient and painful with traditional finger-prick methods. Patients need a less invasive and more continuous way to track their glucose levels to make informed decisions about insulin dosage and lifestyle adjustments.
Solution
Biofi develops and manufactures continuous glucose monitoring (CGM) devices that provide real-time blood sugar data to individuals with diabetes. These devices use a small sensor inserted under the skin to continuously measure glucose levels in interstitial fluid. The data is then transmitted wirelessly to a receiver or smartphone app, allowing users to track their glucose trends, set alerts for high or low levels, and make proactive adjustments to their insulin and diet. Biofi's CGM technology aims to improve glycemic control, reduce the risk of hypoglycemic events, and enhance the overall quality of life for people living with diabetes.
Target Audience
Biofi's primary customers are individuals with type 1 and type 2 diabetes who require continuous glucose monitoring to manage their condition effectively.
Features
- Real-time glucose readings displayed on a receiver or smartphone app
- Trend arrows indicating the direction and rate of glucose change
- Customizable alerts for high and low glucose levels
- Data logging and reporting for tracking glucose patterns over time
- Integration with insulin pumps for automated insulin delivery (AID) systems
- User-friendly interface for easy data interpretation and management